# Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable

Source: https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/  
OnCo record `idea-tr1-extended-interval-checkpoint-dosing` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immunotherapy antibodies stay active in the body for weeks, yet are often given every two or three weeks. After a few months, spacing doses out to every two or three months might work as well, with fewer hospital visits and much lower cost.

## Summary

Non-inferiority trials randomising patients with response or stable disease after 3-6 months of PD-1/PD-L1 blockade to extended-interval dosing (e.g., every 8-12 weeks, PK-guided) versus standard intervals, with PFS or TTF non-inferiority and cumulative dose, cost and toxicity as secondaries. Receptor occupancy studies show saturation at exposures far below label; PK-guided interval extension has been piloted.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Extended-interval dosing in responders will be non-inferior for PFS with at least 50 percent lower cumulative drug exposure and fewer immune-related adverse events requiring intervention.
- Rationale: PD-1 receptor occupancy on circulating T cells is saturated at low concentrations and persists for months; the half-life of these antibodies is around three weeks, and dosing intervals were set for trial convenience and revenue rather than pharmacology.
- Proposed test: A cooperative-group non-inferiority trial in NSCLC and melanoma responders, powered for a pre-agreed PFS margin, with PK sampling to support a label change.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Wrong doses): FDA Oncology Center of Excellence, Project Optimus: https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- trials: [CheckMate 227](https://onco.cc/trials/checkmate-227/), [CheckMate 915](https://onco.cc/trials/checkmate-915/), [Fianlimab + cemiplimab phase 3 (first-line melanoma)](https://onco.cc/trials/fianlimab-phase3-melanoma/), [KEYNOTE-042](https://onco.cc/trials/keynote-042/), [RELATIVITY-098](https://onco.cc/trials/relativity-098/)
- bottlenecks: [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/), [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- key papers: [KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-keynote-010-lancet-2016/), [KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer](https://onco.cc/key-papers/paper-keynote-024-nejm-2016/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/)

---
JSON: https://onco.cc/api/v1/entities/idea-tr1-extended-interval-checkpoint-dosing.json